{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:49:41Z","timestamp":1777866581791,"version":"3.51.4"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Maintenance chemotherapy prolongs progression-free survival (PFS) in several malignancies, but its role in soft tissue sarcoma (STS) remains unclear. Conventional doxorubicin is limited by cumulative toxicities. Liposomal doxorubicin may allow prolonged therapy. We evaluated outcomes of patients treated with maintenance liposomal doxorubicin following induction doxorubicin. This was a single-center retrospective study using the Quebec Sarcoma Registry from 2015 to 2025. Eligible patients had histologically confirmed STS and received doxorubicin-based induction therapy. Those achieving disease control were treated with maintenance liposomal doxorubicin. Clinical variables, adverse events, and outcomes were collected, and PFS and overall survival (OS) were estimated using the Kaplan\u2013Meier method. Twenty-four patients were included (median age 61 years; 62.5% male), with leiomyosarcoma and undifferentiated pleomorphic sarcoma as the most frequent histologies. The median induction exposure was six cycles, and maintenance treatment was administered for a median of five cycles. Median PFS was 11.4 months, and median maintenance PFS was 6.1 months. Infusion reactions and hematologic toxicities were the most common adverse events. Median OS was 60.2 months. Maintenance liposomal doxorubicin was feasible, well-tolerated, and associated with encouraging disease control in selected patients, supporting further prospective evaluation.<\/jats:p>","DOI":"10.3390\/curroncol33050260","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:03:47Z","timestamp":1777536227000},"page":"260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study"],"prefix":"10.3390","volume":"33","author":[{"suffix":"Junior","given":"Alexandre Da Silva","family":"Faco","sequence":"first","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 0B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-4224","authenticated-orcid":false,"given":"Mohammad Amin","family":"Salehi","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 0B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-3828","authenticated-orcid":false,"given":"Mohammad Hassan","family":"Hodroj","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 0B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8913-9049","authenticated-orcid":false,"given":"Kaveh","family":"Mozafari-Lorestani","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 0B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras A.","family":"Moria","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Noujaim","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-9316","authenticated-orcid":false,"given":"Ramy R.","family":"Saleh","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 0B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/EDBK_205423","article-title":"More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments","volume":"38","author":"Katz","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1159\/000509519","article-title":"Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years","volume":"43","author":"Lochner","year":"2020","journal-title":"Oncol. Res. Treat."},{"key":"ref_3","unstructured":"American Cancer Society (2026, March 24). Survival Rates for Soft Tissue Sarcomas. Available online: https:\/\/www.cancer.org\/cancer\/types\/soft-tissue-sarcoma\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_4","unstructured":"National Cancer Institute (2022). SEER Cancer Statistics Review: Soft Tissue Sarcoma Survival, Bethesda, MD, USA."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ray-Coquard, I., Collard, O., Ducimetiere, F., Laramas, M., Mercier, F., Ladarre, N., Manson, S., Tehard, B., Clippe, S., and Suchaud, J.-P. (2017). Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS). BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3057-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): An international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-lnduced congestive heart failure","volume":"91","author":"Layard","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/med.21280","article-title":"Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy","volume":"34","author":"Carvalho","year":"2014","journal-title":"Med. Res. Rev."},{"key":"ref_11","unstructured":"(2003). Doxorubicin Hydrochloride Injection: Prescribing Information, U.S. Food and Drug Administration."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/JTO.0b013e3181d86e8b","article-title":"Maintenance therapy in advanced non-small cell lung cancer","volume":"5","author":"Coate","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14694\/EdBook_AM.2013.33.9","article-title":"Early and late long-term effects of adjuvant chemotherapy","volume":"33","author":"Mayer","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00404-019-05104-0","article-title":"Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: A retrospective study","volume":"299","author":"Blake","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_20","unstructured":"(2025). Sarcoma Research Consortium of Quebec, Sarcoma Research Consortium of Quebec."},{"key":"ref_21","unstructured":"(2022). Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans\u2014TCPS 2, Government of Canada PoRE."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_23","unstructured":"(2017). Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, U.S. Department of Health and Human Services NCI, Division of Cancer Treatment and Diagnosis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_25","first-page":"100748","article-title":"Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy","volume":"45","author":"Willmann","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13569-020-00137-5","article-title":"Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: An EORTC-STBSG database study","volume":"10","author":"Verschoor","year":"2020","journal-title":"Clin. Sarcoma Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\u00ae\/CAELYX\u00ae) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1006429907449","article-title":"Phase II trial of liposomal doxorubicin (Doxil\u00ae) in advanced soft tissue sarcomas","volume":"18","author":"Chidiac","year":"2000","journal-title":"Investig. New Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/DDDT.S140638","article-title":"Aldoxorubicin: A tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas","volume":"12","author":"Gong","year":"2018","journal-title":"Drug. Des. Dev. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-22-1903","article-title":"Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial","volume":"28","author":"Wang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.annonc.2025.03.024","article-title":"Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: A double-blind randomised trial","volume":"36","author":"Penel","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(15)70031-8","article-title":"Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): A randomised phase 2 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","article-title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): A randomised, multicentre, open-label phase 3 trial","volume":"23","author":"Pautier","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1200\/OP.20.00692","article-title":"Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non\u2013Small-Cell Lung Cancer","volume":"17","author":"Goulart","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:54:40Z","timestamp":1777539280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050260"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050260","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}